GILD•benzinga•
Gilead's Livdelzi (Seladelpar) Shows Sustained Efficacy And Long-Term Safety In Primary Biliary Cholangitis; 81% Achieve Biochemical Response By Month 30, 41% Reach ALP Normalization, And 27% Experience Near Resolution Of Itch In Phase 3 ASSURE Study
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga